Home | All trials

[RDF data]
Trial NCT00000492

Resource URI: http://static.linkedct.org/resource/trials/NCT00000492
PropertyValue
linkedct:brief_title Beta-Blocker Heart Attack Trial (BHAT)
linkedct:condition <http://static.linkedct.org/resource/condition/1156>
linkedct:condition <http://static.linkedct.org/resource/condition/13752>
linkedct:condition <http://static.linkedct.org/resource/condition/2312>
linkedct:condition <http://static.linkedct.org/resource/condition/3388>
linkedct:condition <http://static.linkedct.org/resource/condition/3593>
linkedct:condition <http://static.linkedct.org/resource/condition/5702>
linkedct:condition <http://static.linkedct.org/resource/condition/8483>
linkedct:condition <http://static.linkedct.org/resource/condition/8489>
linkedct:criteria Men and women, ages 30 to 69. Documented myocardial infarction.
linkedct:description BACKGROUND: Survivors of a documented myocardial infarction are recognized as having a high risk of dying relative to the general population. Serious arrhythmias, occurring with or without evidence of new infarction, are a common cause of death in this population. Theoretically, an agent which (1) can block the sympathetic nervous activity thought to be involved in precipitating sudden death and (2) has non-neurogenic antiarrhythmic properties would be of value to people with coronary heart disease. Propranolol, like other beta- blocking agents, has these as well as other properties and therefore might be expected to prevent or retard complications of coronary heart disease such as serious arrhythmias. This would be reflected in a decrease in mortality due to coronary heart disease. A workshop on chronic antiarrhythmic therapy reviewed contemporary experimental data and clinical practice and recommended that a clinical trial be undertaken to clearly show the effects of beta-blocking drugs on mortality. Subsequently, such a trial was approved by the Clinical Applications and Prevention Advisory Committee, by the Cardiology Advisory Committee, and by the National Heart, Lung, and Blood Advisory Council. The study protocol was reviewed in February 1978 and recommended for approval by the policy-data monitoring board and ad hoc members. The protocol was approved by the Director of NHLBI in March 1978. Recruitment started on June 19, 1978, and ended in October 1980. A total of 3,837 patients were randomized. Units which participated in the trial included 32 clinical centers, an EKG center, a central laboratory, a coordinating center, a 1-hour ambulatory ECG center, a 24-hour ambulatory EKG center, and an EKG tape quality control center. DESIGN NARRATIVE: A randomized, double-blind design with single experimental and control groups. Patients were recruited while in the hospital for an acute myocardial infarction and were enrolled in the study before discharge. Eligible patients fulfilled the study definition of an acute myocardial infarction. The diagnosis was based either on electrocardiographic records showing evolving QRS segment changes or on ST segment and T wave changes together with enzyme changes and appropriate clinical history. One-half of the patients were placed on therapy using a beta-blocking drug (propranolol). The other half received a placebo. The prescribed maintenance dosage of propranolol was either l80 or 240 mgs/day, depending upon serum drug levels. Intervention duration averaged 25 months.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 69 Years
linkedct:eligibility_minimum_age 30 Years
linkedct:end_date October 1981
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 27, 1999
linkedct:id NCT00000492
rdfs:label Trial NCT00000492
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Heart, Lung, and Blood Institute (NHLBI)
linkedct:nct_id NCT00000492
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id 11
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/12840>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/15206>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/15307>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/1711>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/18360>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/18409>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/19260>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/19735>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/20519>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/24350>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/25354>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/25422>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/28347>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/28915>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/28919>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/31092>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/35856>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/39057>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/43477>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/44506>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/45066>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/46111>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/46640>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/46789>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/47464>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/47642>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/49612>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/49920>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/50411>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/50754>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/50757>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/50967>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/51055>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/57809>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/61459>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/839>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/8603>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000492>
linkedct:phase Phase 3
linkedct:reference <http://static.linkedct.org/resource/reference/1313>
linkedct:reference <http://static.linkedct.org/resource/reference/37617>
linkedct:reference <http://static.linkedct.org/resource/reference/38390>
linkedct:reference <http://static.linkedct.org/resource/reference/38430>
linkedct:reference <http://static.linkedct.org/resource/reference/38570>
linkedct:reference <http://static.linkedct.org/resource/reference/39049>
linkedct:reference <http://static.linkedct.org/resource/reference/39116>
linkedct:reference <http://static.linkedct.org/resource/reference/39697>
linkedct:reference <http://static.linkedct.org/resource/reference/40021>
linkedct:reference <http://static.linkedct.org/resource/reference/406>
linkedct:reference <http://static.linkedct.org/resource/reference/40643>
linkedct:reference <http://static.linkedct.org/resource/reference/41159>
linkedct:reference <http://static.linkedct.org/resource/reference/41270>
linkedct:reference <http://static.linkedct.org/resource/reference/41293>
linkedct:reference <http://static.linkedct.org/resource/reference/41934>
linkedct:reference <http://static.linkedct.org/resource/reference/41937>
linkedct:reference <http://static.linkedct.org/resource/reference/41963>
linkedct:reference <http://static.linkedct.org/resource/reference/42125>
linkedct:reference <http://static.linkedct.org/resource/reference/42189>
linkedct:reference <http://static.linkedct.org/resource/reference/42261>
linkedct:reference <http://static.linkedct.org/resource/reference/42274>
linkedct:reference <http://static.linkedct.org/resource/reference/42996>
linkedct:reference <http://static.linkedct.org/resource/reference/42997>
linkedct:reference <http://static.linkedct.org/resource/reference/43004>
linkedct:reference <http://static.linkedct.org/resource/reference/43015>
linkedct:reference <http://static.linkedct.org/resource/reference/43029>
linkedct:reference <http://static.linkedct.org/resource/reference/43039>
linkedct:reference <http://static.linkedct.org/resource/reference/43045>
linkedct:reference <http://static.linkedct.org/resource/reference/43046>
linkedct:reference <http://static.linkedct.org/resource/reference/43283>
linkedct:reference <http://static.linkedct.org/resource/reference/43284>
linkedct:reference <http://static.linkedct.org/resource/reference/43313>
linkedct:reference <http://static.linkedct.org/resource/reference/43332>
linkedct:reference <http://static.linkedct.org/resource/reference/43994>
linkedct:reference <http://static.linkedct.org/resource/reference/44010>
linkedct:reference <http://static.linkedct.org/resource/reference/44197>
linkedct:reference <http://static.linkedct.org/resource/reference/44221>
linkedct:reference <http://static.linkedct.org/resource/reference/48409>
linkedct:source National Heart, Lung, and Blood Institute (NHLBI)
linkedct:start_date September 1977
linkedct:study_design Prevention, Randomized, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period. Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event. One-half of the patients were randomly assigned to a beta-blocking drug (propranolol) and one-half to a placebo. The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction.
rdf:type linkedct:trials
linkedct:verification_date October 1981